«Immune checkpoint inhibitors, including PD - 1 and PD - L1 inhibitors, have provided meaningful clinical benefits for patients with cancer; however,
novel immunotherapy combination treatments are needed to improve efficacy with limited additive toxicity,» said Aung Naing, MD, FACP, associate professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.
Phase 1b study of
a novel immunotherapy combination therapy of intralesional Coxsackievirus A21 and systemic ipilimumab in patients with advanced melanoma.
Results from a recent clinical trial to treat lung cancer show that
a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.
In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that
a novel immunotherapy combination is surprisingly effective at controlling the disease's progression.
Not exact matches
These therapies could enhance the effects of
novel cancer
immunotherapies when used in
combination, resulting in better health outcomes for cancer patients.
She has identified
novel immune - modulating activities associated with targeted cancer drugs in preclinical models, and developed synergistic
immunotherapy combinations.
Upcoming interventional trials will examine
immunotherapy in
combination with other
novel agents in an effort to improve both short - and long - term outcomes for patients.
The
combination of rituximab (Rituxan) and the
novel immunotherapy pidilizumab (CT - 011) is both active and well tolerated in follicular lymphoma patients, according to results of a phase II trial presented by Jason R. Westin, MD, of the MD Anderson Cancer Center in Houston, at the American Society of Hematology (ASH) meeting in Atlanta.
To combat the nation's third deadliest cancer, the phase 1b / 2 open - label study will explore the
combination of standard chemotherapy and two
immunotherapy agents: an anti-PD-1 checkpoint inhibitor and a
novel antibody targeting CD40, a protein that when activated can drive the immune system to attack tumors.
The company uses a unique platform to identify rational
combinations of
immunotherapies and
novel targets.
The Delaney Collaboratory to Cure HIV - 1 Infection by
Combination Immunotherapy (BEAT - HIV Collaboratory) is a consortium of more than 30 top HIV researchers from leading academic research institutions working with government, nonprofit organizations, and industry partners to test
combinations of several
novel immunotherapies under new preclinical research and clinical trials.
Here we describe the results of a
novel type of complementary
immunotherapy of cancer that is based on a
combination of ketogenic diet, administration of an emulsion made of chondroitin sulfate, vitamin D3 and oleic acid and of a fermented milk and colostrum product.